Abiopharma

🔍 Merson James (Director)

Company: Cidara Therapeutics, Inc. (CDTX)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Sold 4,250 shares of Stock Option (right to buy) at $12.63 per share (Derivative)
  Date: 2026-01-07 | Code: D | Expires: 2034-04-25 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 2,125 shares of Stock Option (right to buy) at $12.64 per share (Derivative)
  Date: 2026-01-07 | Code: D | Expires: 2034-07-17 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 11,100 shares of Stock Option (right to buy) at $21.31 per share (Derivative)
  Date: 2026-01-07 | Code: D | Expires: 2035-06-17 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1

Footnotes:

• F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger").
• F2: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.